Video

Dr. Palmer on Symptom Burden in Myelofibrosis With Thrombocytopenia

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

Jeanne M. Palmer, MD, vice chair, section chief, Hematology, program director, the Blood and Marrow Transplant Program, Mayo Clinic; instructor, the Mayo Clinic Medical School; instructor, the University of Arizona, discusses total symptom scores (TSS) in patients with myelofibrosis with thrombocytopenia.

A retrospective analysis of the phase 3 PERSIST-1 (NCT01773187) and PAC203 (NCT04884191) trials analyzed the symptom burdens of patients with myelofibrosis, including those with isolated thrombocytopenia or isolated anemia. This study used TSS v1.0 and v2.0 to analyze inflammatory symptoms including night sweats, weight loss, and fatigue, as well as spleen symptoms such as abdominal discomfort, left-sided rib pain, and early satiety, Palmer says.

Generally, patients with isolated thrombocytopenia had higher TSS, including higher fatigue scores than those with isolated anemia, Palmer notes. Although the reasons for these differences in the TSS data across myelofibrosis cohorts are unknown, it is possible that since patients with thrombocytopenia typically have more advanced disease, their symptom burdens may be associated with their increased disease progression, Palmer explains. Additionally, thrombocytopenia may intrinsically cause fatigue, which may also be true in other disease types, such as immune thrombocytopenia, in which patients often present with increased fatigue, Palmer concludes.

Funding supported by CTI Biopharma. Content independently developed by OncLive

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
R. Lor Randall, MD, FACS
Joshua Richter, MD of Tisch Cancer Institute
Guenther Koehne, MD, deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, Baptist Health South Florida
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Bradley McGregor, MD
Katherine L. Nathanson, MD
Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School
Julie M. Vose, MD, MBA
6369343864112
Matthew Wagar, MD of the University of Wisconsin School of Medicine and Public Health